Decursin exerts anti-cancer activity in MDA-MB-231 breast cancer cells via inhibition of the Pin1 activity and enhancement of the Pin1/p53 association.
Ji-Hyun Kim, Ji Hoon Jung, Sung-Hoon Kim, Soo-Jin Jeong
Index: Phytother Res. 28(2) , 238-44, (2014)
Full Text: HTML
Abstract
The peptidyl-prolyl cis/trans isomerase Pin1 is overexpressed in a wide variety of cancer cells and thus considered as an important target molecule for cancer therapy. This study demonstrates that decursin, a bioactive compound from Angelica gigas, exert the anti-cancer effect against breast cancer cells via regulation of Pin1 and its related signaling molecules. We observed that decursin induced G1 arrest with decrease in cyclin D1 level in Pin1-expressing breast cancer cells MDA-MB-231, but not Pin1-non-expressing breast cancer cells MDA-MB-157. In addition, decursin significantly reduced protein expression and enzymatic activity of Pin1 in MDA-MB-231 cells. Further, we found that decursin treatment enhanced the p53 expression level and failed to down-regulate Pin1 in the cells transfected with p53 siRNA, indicating the importance of p53 in the decursin-mediated Pin1 inhibition in MDA-MB-231 cells. Decursin stimulated association between Pin1 to p53. Moreover, decursin facilitated p53 transcription in MDA-MB-231 cells. Overall, our current study suggests the potential of decursin as an attractive cancer therapeutic agent for breast cancer by targeting Pin1 protein.Copyright © 2013 John Wiley & Sons, Ltd.
Related Compounds
Related Articles:
2014-07-17
[Life Sci. 108(2) , 94-103, (2014)]
2012-10-01
[J. Med. Food 15(10) , 863-72, (2012)]
2011-11-01
[Indian J. Exp. Biol. 49(11) , 848-56, (2011)]
Biopharmaceutical characterization of decursin and their derivatives for drug discovery.
2013-10-01
[Drug Dev. Ind. Pharm. 39(10) , 1523-30, (2013)]
2012-07-01
[Cell Biol. Int. 36(7) , 683-8, (2012)]